Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation

Haematologica

Volumn 85, Issue 9, 2000, Pages 930-934

  Martinelli, G ^a   Terragna, C ^a   Zamagni, E ^a   Ronconi, S ^a   Tosi, P ^a   Lemoli, R M ^a   Bandini, G ^a   Testoni, N ^a   Amabile, M ^a   Ottaviani, E ^a   Buonamici, S ^a   Soverini, S ^a   Montefusco, V ^a   De Vivo, A ^a   Bonifazi, F ^a   Tura, S ^a   Cavo, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Allogeneic bone marrow transplantation; Minimal residual disease; Multiple myeloma; PCR

Indexed keywords

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN GENE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION;

ADULT; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; MALE; MIDDLE AGE; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; RECURRENCE; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 20244366969     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: Biological and clinical implications
2. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients
3. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain gene
4. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma
5. The role of haemopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma
6. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
7. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma
8. Total therapy with tandem transplants for newly diagnosed multiple myeloma
9. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: An Italian multicenter study
10. Prognostic Factors in allogeneic bone marrow transplantation for multiple myeloma
11. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
12. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma
13. Gene-marking to trace the origin of relapse after autologous bone-marrow transplantation
14. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells
15. Selection and transplantation of autologous CD34+B-lineage negative cells in advanced phase multiple myeloma patients: A pilot study
16. Graft-versus-myeloma effect in two cases
17. Graft-versus-myeloma
18. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: A case report
19. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation
20. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
21. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation
22. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
23. Transplantation of CD34+ peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma
24. Molecular remission after allogeneic or autologous transplantalion of hematopoietic stem cells for multiple myeloma
25. Molecular and clinical remission in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
26. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells
27. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?
28. A new method of 'in cell RT-PCR' for the detection of BCR-ABL transcript in chronic myeloid leukemia patients
29. Improved tools for biological sequence comparison
30. Treatment of multiple myeloma
31. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: A retrospective comparison of short-term outcome with bone marrow transplantation
32. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation
33. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
34. Eradication of PCR detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation
35. Treatment of chronic myelogenous leukemia: Current status and investigational options
36. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
37. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
38. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes